Altimmune, Inc.: management transactions · United States · SEC (Form 4)

About Altimmune, Inc.

Altimmune, Inc. is a U.S.-listed biotechnology company trading on the Nasdaq (United States) and focused on developing therapies for serious liver diseases. The company is a late clinical-stage biopharmaceutical developer whose strategy is now centered on pemvidutide, its lead candidate, which is being advanced across metabolic and liver-related indications with meaningful unmet medical need. Altimmune is headquartered in Gaithersburg, Maryland, placing it in one of the key biopharma hubs on the U.S. East Coast. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial)) From a historical perspective, Altimmune was founded in 1997. The company’s current corporate form reflects a major strategic evolution, including the merger with PharmAthene completed in 2017, after which the combined entity began trading as Altimmune, Inc. on Nasdaq under ticker ALT. Over time, the business has shifted from a broader vaccine/immunotherapeutics profile toward a narrower, higher-conviction clinical focus built around pemvidutide and the liver-disease opportunity set. ([stockanalysis.com](https://stockanalysis.com/stocks/alt/company/?utm_source=openai)) Operationally, Altimmune is now highly concentrated on pemvidutide development in MASH (metabolic dysfunction-associated steatohepatitis), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Management disclosed that pemvidutide has received FDA Breakthrough Therapy Designation in MASH, that the global PERFORMA Phase 3 MASH trial is planned for initiation in the second half of 2026, and that topline data from the RECLAIM Phase 2 AUD study are expected in the third quarter of 2026. The RESTORE Phase 2 ALD trial is also progressing, making the company’s 2026 calendar unusually catalyst-rich for a single-asset biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm)) In competitive terms, Altimmune remains a relatively small player versus large pharmaceutical companies and better-capitalized biotech peers targeting liver and metabolic disease. Its investment case rests on whether pemvidutide can demonstrate a differentiated efficacy/tolerability profile and whether that profile can translate into clinical, regulatory, and ultimately commercial value. The company itself has emphasized pemvidutide’s potential to address critical unmet needs, especially in MASH, where approved therapies have not eliminated substantial room for differentiation. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial)) Recent developments are important for investors. In April 2026, Altimmune closed an oversubscribed public offering that generated gross proceeds of $225 million, explicitly framed as funding for the Phase 3 MASH program and extending cash runway through the anticipated 52-week readout. In its first-quarter 2026 update, the company reported approximately $535 million in cash, cash equivalents and short-term investments as of April 30, 2026. For investors tracking SEC Form 4 insider transactions, these financing and governance disclosures, alongside insider filings, make Altimmune a closely watched small-cap biotech name with significant event-driven potential. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-closing-225-million-oversubscribed-public))